Literature DB >> 19468865

TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset.

Carla Pinto1, Isabel Veiga, Manuela Pinheiro, Ana Peixoto, Armando Pinto, José M Lopes, Rui M Reis, Carla Oliveira, Manuela Baptista, Lúcia Roque, Fernando Regateiro, Luís Cirnes, Robert M W Hofstra, Raquel Seruca, Sérgio Castedo, Manuel R Teixeira.   

Abstract

The Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant disease caused by TP53 germline mutations. This study aimed to characterize the TP53 mutational spectrum in patients suspected to have LFS in Portugal and to evaluate the influence of the MDM2-SNP309 and TP53-72Arg variants and of telomere length on age of tumor onset. Probands were primarily selected using the classical LFS criteria (two cases) or the more sensitive Chompret Li-Fraumeni-like (LFL) criteria (13 cases), but 12 additional patients that did not comply with those LFS or LFL criteria were included in the analysis based on clinical suspicion (LFS suspects). Nine of the 27 probands (33.3%) presented germline TP53 mutations, two of them occurring de novo and two of them being novel. Three of the nine TP53 mutations were found in families that did not comply with any of the commonly used criteria for TP53 testing, leaving room to recommend the use of less stringent criteria. An association was found between the presence of the TP53-72Arg (but not the MDM2-SNP309) variant and earlier age of onset in TP53 carriers. A negative correlation between telomere length and age of cancer onset was found in patients with germline TP53 mutation, whereas no such correlation was found in controls or in patients with wild-type TP53.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19468865     DOI: 10.1007/s10689-009-9251-y

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  41 in total

1.  Telomeric length in individuals and cell lines with altered p53 status.

Authors:  P A Kruk; V A Bohr
Journal:  Radiat Oncol Investig       Date:  1999

2.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.

Authors:  G Bougeard; S Baert-Desurmont; I Tournier; S Vasseur; C Martin; L Brugieres; A Chompret; B Bressac-de Paillerets; D Stoppa-Lyonnet; C Bonaiti-Pellie; T Frebourg
Journal:  J Med Genet       Date:  2005-10-28       Impact factor: 6.318

3.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.

Authors:  R C Ribeiro; F Sandrini; B Figueiredo; G P Zambetti; E Michalkiewicz; A R Lafferty; L DeLacerda; M Rabin; C Cadwell; G Sampaio; I Cat; C A Stratakis; R Sandrini
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 4.  Germline TP53 mutations and Li-Fraumeni syndrome.

Authors:  J M Varley
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

Review 5.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors.

Authors:  A C Latronico; E M Pinto; S Domenice; M C Fragoso; R M Martin; M C Zerbini; A M Lucon; B B Mendonca
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

7.  Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients.

Authors:  G Keller; H Vogelsang; I Becker; S Plaschke; K Ott; G Suriano; A R Mateus; R Seruca; K Biedermann; D Huntsman; C Döring; E Holinski-Feder; A Neutzling; J R Siewert; H Höfler
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

8.  Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age.

Authors:  Marie Trkova; Kamila Prochazkova; Vera Krutilkova; David Sumerauer; Zdenek Sedlacek
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

9.  Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation.

Authors:  Y Horio; H Suzuki; R Ueda; T Koshikawa; T Sugiura; Y Ariyoshi; K Shimokata; T Takahashi; T Takahashi
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

10.  Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53.

Authors:  J M Birch; J Heighway; M D Teare; A M Kelsey; A L Hartley; K J Tricker; D Crowther; D P Lane; M F Santibáñez-Koref
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more
  8 in total

1.  A concurrent episode of two neoplasms in a toddler-age child.

Authors:  Muaz A Alrazzak; Jenny Zablahalabi; Baraa Alrazzak; Guillermo De Angulo
Journal:  Avicenna J Med       Date:  2014-04

2.  p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.

Authors:  Gabriel S Macedo; Igor Araujo Vieira; Fernanda Salles Luiz Vianna; Barbara Alemar; Juliana Giacomazzi; Ana Paula Carneiro Brandalize; Maira Caleffi; Sahlua Miguel Volc; Henrique de Campos Reis Galvão; Edenir Inez Palmero; Maria Isabel Achatz; Patricia Ashton-Prolla
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

3.  Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.

Authors:  Matthew B Yurgelun; Serena Masciari; Victoria A Joshi; Rowena C Mercado; Noralane M Lindor; Steven Gallinger; John L Hopper; Mark A Jenkins; Daniel D Buchanan; Polly A Newcomb; John D Potter; Robert W Haile; Raju Kucherlapati; Sapna Syngal
Journal:  JAMA Oncol       Date:  2015-05       Impact factor: 31.777

Review 4.  The Inherited p53 Mutation in the Brazilian Population.

Authors:  Maria Isabel Achatz; Gerard P Zambetti
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

5.  Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche.

Authors:  Pan Pantziarka
Journal:  Ecancermedicalscience       Date:  2015-05-21

Review 6.  Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Authors:  Pan Pantziarka; Sarah Blagden
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

7.  The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.

Authors:  Carla Escudeiro; Carla Pinto; Joana Vieira; Ana Peixoto; Pedro Pinto; Manuela Pinheiro; Catarina Santos; Joana Guerra; Susana Lisboa; Rui Santos; João Silva; Conceição Leal; Nuno Coimbra; Paula Lopes; Marco Ferreira; Ana B Sousa; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2020-10-14       Impact factor: 2.375

8.  Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p.

Authors:  Diego Davila Paskulin; Juliana Giacomazzi; Maria Isabel Achatz; Sandra Costa; Rui Manoel Reis; Pierre Hainaut; Sidney Emanuel Batista dos Santos; Patricia Ashton-Prolla
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.